Premium
Effects of octreotide on liver regeneration and tumour growth in the regenerating liver
Author(s) -
DAVIES N,
YATES J,
KYNASTON H,
TAYLOR BA,
JENKINS SA
Publication year - 1997
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1997.tb00345.x
Subject(s) - octreotide , liver regeneration , medicine , somatostatin , hepatectomy , endocrinology , regeneration (biology) , mononuclear phagocyte system , gastroenterology , pathology , resection , surgery , biology , microbiology and biotechnology
The ability of the liver to regenerate following resection is remarkable. However, there is evidence to suggest that tumour growth within the regenerating liver is significantly increased. As octreotide (a synthetic analogue of somatostatin) inhibits the growth and development of hepatic tumour in rats, we have investigated its effects on liver regeneration, liver blood flow, hepatic reticuloendothelial system activity and tumour growth in the rat following partial hepatectomy (PH). Octreotide significantly inhibited liver regeneration in the rat 1 and 2 weeks following PH when compared with controls (regeneration index: 1.0 and 1.14 cf. 1.14 and 1.4, respectively). There was no significant difference in hepatic arterial or portal venous blood flow following PH in control or octreotide‐treated rats. However, portal pressure was significantly reduced in octreotide‐treated rats. Hepatic reticuloendothelial system activity was significantly increased in octreotide‐treated rats compared with control animals 1 and 2 weeks after hepatectomy (uptake of radiolabelled technetium‐99 m albumin colloid: 2.2 and 3.9 cf. 1.6 and 1.9). The growth of both HSN (fibrosarcoma) and K12‐Tr (colonic adenocarcinoma) cells in the regenerating liver was significantly decreased by octreotide treatment compared with controls (median percentage hepatic replacement: HSN control 71.3%, Octreotide 8.4%, K12‐Tr Control 38.3%, Octreotide 4.5%). The results of the present study demonstrate that octreotide inhibits both liver regeneration and tumour growth following PH, possibly via a similar mechanism.